NEP-Inhibitoren zur Behandlung von weiblichen sexuellen Störungen

A pharmaceutical composition (C1) comprising an inhibitor of neutral endopeptidase (NEP) (a1) with carrier, diluent or excipient optionally with additional pharmaceutical agent (preferably NEP, phosphodiesterase (PDE) and/or neuropeptide Y (NPY) inhibitor), is new. Independent claims are included fo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	WAYMAN, CHRISTOPHER PETER, MAW, GRAHAM NIGEL
Format:	Patent
Sprache:	ger
Schlagworte:	ACYCLIC OR CARBOCYCLIC COMPOUNDS AGRICULTURE ANIMAL HUSBANDRY BEER BIOCHEMISTRY CARE OF BIRDS, FISHES, INSECTS CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY FISHING FORESTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HUNTING HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING NEW BREEDS OF ANIMALS ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING TRAPPING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A pharmaceutical composition (C1) comprising an inhibitor of neutral endopeptidase (NEP) (a1) with carrier, diluent or excipient optionally with additional pharmaceutical agent (preferably NEP, phosphodiesterase (PDE) and/or neuropeptide Y (NPY) inhibitor), is new. Independent claims are included for: (1) performing an assay method for identifying an agent that can be used to treat female sexual dysfunction (FSD) involving determining whether an agent can directly or indirectly potentiate cyclic adenosine-3',5'-monophosphate (cAMP) where a potentiation of cAMP in the presence of the agent is indicative that the agent can be useful in the treatment of FSD where the agent is (a1), identifying at least one agent that can directly or indirectly potentiate cAMP, preparing the identified agents, mixing the identified agent with carrier, diluent or excipient to form (C1), and packaging (C1); (2) an assay process for identifying an agent that can treat FSD involving administering an agent to an animal model, measuring any potentiation of cAMP and/or increase in blood flow in the genitalia of the animal, where the agent is (a1) and the animal model comprises at least one of an anesthetized female animal including device to measure changes in genital blood flow of the animal following stimulation of the pelvic nerve where the agent potentiates cAMP in the sexual genitalia following optionally oral administration; (3) a diagnostic method involving isolating a sample from a female, determining whether the sample contains an entity (e1) to cause FSD, whether the entity has a direct or indirect effect on the level of activity of cAMP in the sexual genitalia of the female and whether the entity can be modulated to achieve a beneficial effect by using (a1); and (4) a diagnostic kit comprising device for detecting (e1) in an isolated female sample, and (a1). ACTIVITY : Endocrine-Gen. MECHANISM OF ACTION : Neutral endopeptidase (NEP) inhibitor; Mediator of female genital vasorelaxation. Test details are described but no results for the specific compounds given.